6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Severe	NNP	severe	severe	sever	N	B-Severity
or	CC	or	or	or	N	O
Persistent	NNP	persistent	persistent	persist	N	B-Severity
Gastrointestinal	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
Toxicity	NNP	toxicity	toxicity	toxic	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O

Hepatotoxicity	NNP	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O

Interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
Lung	NNP	lung	lung	lung	N	I-AdverseReaction
Disease	NNP	disease	disease	diseas	N	I-AdverseReaction
Pneumonitis	NNP	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O

QT	NNP	qt	qt	qt	N	B-AdverseReaction
Interval	NNP	interval	interval	interv	N	I-AdverseReaction
Prolongation	NNP	prolongation	prolongation	prolong	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.2	CD	12.2	12.2	12.2	N	O
)]	NN	)]	)]	)]	N	O

Hyperglycemia	NNP	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O

Bradycardia	NNP	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.2	CD	12.2	12.2	12.2	N	O
)]	NN	)]	)]	)]	N	O

Pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)]	NN	)]	)]	)]	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
diarrhea	JJ	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
elevated	JJ	elevated	elevated	elev	N	B-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Novartis	NNP	novartis	novartis	novarti	N	O
Pharmaceuticals	NNP	pharmaceuticals	pharmaceutical	pharmaceut	N	O
Corporation	NNP	corporation	corporation	corpor	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
888	CD	888	888	888	N	O
-	:	-	-	-	N	O
669	CD	669	669	669	N	O
-	:	-	-	-	N	O
6682	CD	6682	6682	6682	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
is	VBZ	is	is	is	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
255	CD	255	255	255	N	O
ALK	NNP	alk	alk	alk	N	O
-	:	-	-	-	N	O
positive	JJ	positive	positive	posit	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
246	CD	246	246	246	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
NSCLC	NNP	nsclc	nsclc	nsclc	N	O
and	CC	and	and	and	N	O
9	CD	9	9	9	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
cancers	NNS	cancers	cancer	cancer	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
750	CD	750	750	750	N	O
mg	NNS	mg	mg	mg	N	O
daily	RB	daily	daily	daili	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
was	VBD	was	wa	wa	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
study	NN	study	study	studi	N	O
population	NN	population	population	popul	N	O
characteristics	NNS	characteristics	characteristic	characterist	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
53	CD	53	53	53	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
age	NN	age	age	age	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
65	CD	65	65	65	N	O
(	(	(	(	(	N	O
84%	CD	84%	84%	84%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
female	JJ	female	female	femal	N	O
(	(	(	(	(	N	O
53%	CD	53%	53%	53%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Caucasian	NNP	caucasian	caucasian	caucasian	N	O
(	(	(	(	(	N	O
63%	CD	63%	63%	63%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Asian	NNP	asian	asian	asian	N	O
(	(	(	(	(	N	O
34%	CD	34%	34%	34%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
NSCLC	NNP	nsclc	nsclc	nsclc	N	O
adenocarcinoma	VBZ	adenocarcinoma	adenocarcinoma	adenocarcinoma	Y	O
histology	NN	histology	histology	histolog	Y	O
(	(	(	(	(	N	O
90%	CD	90%	90%	90%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
never	RB	never	never	never	N	O
or	CC	or	or	or	N	O
former	JJ	former	former	former	N	O
smoker	NN	smoker	smoker	smoker	Y	O
(	(	(	(	(	N	O
97%	CD	97%	97%	97%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
ECOG	NNP	ecog	ecog	ecog	N	O
PS	NNP	ps	p	ps	N	O
0	CD	0	0	0	N	O
or	CC	or	or	or	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
89%	CD	89%	89%	89%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
brain	NN	brain	brain	brain	N	O
metastasis	NN	metastasis	metastasis	metastasi	Y	O
(	(	(	(	(	N	O
49%	CD	49%	49%	49%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
prior	JJ	prior	prior	prior	N	O
therapies	NNS	therapies	therapy	therapi	N	O
2	CD	2	2	2	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
(	(	(	(	(	N	O
67%	CD	67%	67%	67%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Dose	NNP	dose	dose	dose	N	O
reductions	NNS	reductions	reduction	reduct	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
59%	CD	59%	59%	59%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
dose	VB	dose	dose	dose	N	O
reductions	NNS	reductions	reduction	reduct	N	O
or	CC	or	or	or	N	O
interruptions	NNS	interruptions	interruption	interrupt	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
(	(	(	(	(	N	O
29%	CD	29%	29%	29%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
AST	NNP	ast	ast	ast	N	I-AdverseReaction
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
were	VBD	were	were	were	N	O
convulsion	NN	convulsion	convulsion	convuls	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
.	.	.	.	.	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
consisting	VBG	consisting	consisting	consist	N	O
of	IN	of	of	of	N	O
:	:	:	:	:	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumothorax	NN	pneumothorax	pneumothorax	pneumothorax	Y	B-AdverseReaction
,	,	,	,	,	N	O
gastric	JJ	gastric	gastric	gastric	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
general	JJ	general	general	gener	N	B-AdverseReaction
physical	JJ	physical	physical	physic	N	I-AdverseReaction
health	NN	health	health	health	N	I-AdverseReaction
deterioration	NN	deterioration	deterioration	deterior	N	I-AdverseReaction
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
tamponade	NN	tamponade	tamponade	tamponad	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
patient	NN	patient	patient	patient	N	O
each	DT	each	each	each	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
were	VBD	were	were	were	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
.	.	.	.	.	N	O

Tables	NNS	tables	table	tabl	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
summarize	VBP	summarize	summarize	summar	N	O
the	DT	the	the	the	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
for	IN	for	for	for	N	O
All	DT	all	all	all	N	O
NCI	NNP	nci	nci	nci	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
Grades	NNP	grades	grade	grade	N	O
or	CC	or	or	or	N	O
2%	CD	2%	2%	2%	N	O
for	IN	for	for	for	N	O
Grades	NNP	grades	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
ALK	NNP	alk	alk	alk	N	O
-	:	-	-	-	N	O
Positive	JJ	positive	positive	posit	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

National	NNP	national	national	nation	N	O
Cancer	NNP	cancer	cancer	cancer	Y	O
Institute	NNP	institute	institute	institut	N	O
Common	NNP	common	common	common	N	O
Terminology	NNP	terminology	terminology	terminolog	N	O
Criteria	NNP	criteria	criterion	criteria	N	O
for	IN	for	for	for	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Events	NNP	events	event	event	N	O
(	(	(	(	(	N	O
version	NN	version	version	version	N	O
4.03	CD	4.03	4.03	4.03	N	O
)	)	)	)	)	N	O
a	DT	a	a	a	N	O
Abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
abdominal	JJ	abdominal	abdominal	abdomin	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
epigastric	JJ	epigastric	epigastric	epigastr	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
)	)	)	)	)	N	O
b	NN	b	b	b	N	O
Esophageal	NNP	esophageal	esophageal	esophag	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
dyspepsia	NN	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
,	,	,	,	,	N	O
gastroesophageal	JJ	gastroesophageal	gastroesophageal	gastroesophag	N	B-AdverseReaction
reflux	NN	reflux	reflux	reflux	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
)	)	)	)	)	N	O
c	NN	c	c	c	N	O
Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
(	(	(	(	(	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
)	)	)	)	)	N	O
d	NN	d	d	d	N	O
Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
(	(	(	(	(	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
maculopapular	JJ	maculopapular	maculopapular	maculopapular	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
,	,	,	,	,	N	O
acneiform	VB	acneiform	acneiform	acneiform	N	B-AdverseReaction
dermatitis	NN	dermatitis	dermatitis	dermat	Y	I-AdverseReaction
)	)	)	)	)	N	O

ZYKADIAN	NN	zykadian	zykadian	zykadian	N	O

255	CD	255	255	255	N	O

All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O

disorders	NNS	disorders	disorder	disord	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
86	CD	86	86	86	N	O
6	CD	6	6	6	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
80	CD	80	80	80	N	O
4	CD	4	4	4	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
60	CD	60	60	60	N	O
4	CD	4	4	4	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
a	DT	a	a	a	N	O
54	CD	54	54	54	N	O
2	CD	2	2	2	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
29	CD	29	29	29	N	O
0	CD	0	0	0	N	O

Esophageal	NNP	esophageal	esophageal	esophag	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
b	VBD	b	b	b	N	O
16	CD	16	16	16	N	O
1	CD	1	1	1	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
c	VBD	c	c	c	N	O
52	CD	52	52	52	N	O
5	CD	5	5	5	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
34	CD	34	34	34	N	O
1	CD	1	1	1	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
d	VBD	d	d	d	N	O
16	CD	16	16	16	N	O
0	CD	0	0	0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
lung	NN	lung	lung	lung	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
pneumonitis	VBD	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
4	CD	4	4	4	N	O
3	CD	3	3	3	N	O

Additional	NNP	additional	additional	addit	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
included	VBD	included	included	includ	N	O
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	B-AdverseReaction
(	(	(	(	(	N	O
17%	CD	17%	17%	17%	N	O
;	:	;	;	;	N	O
comprised	VBN	comprised	comprised	compris	N	O
of	IN	of	of	of	N	O
paresthesia	NN	paresthesia	paresthesia	paresthesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
muscular	JJ	muscular	muscular	muscular	N	B-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction
,	,	,	,	,	N	O
gait	NN	gait	gait	gait	N	B-AdverseReaction
disturbance	NN	disturbance	disturbance	disturb	N	I-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
sensory	NN	sensory	sensory	sensori	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
dysesthesia	NN	dysesthesia	dysesthesia	dysesthesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
neuralgia	RB	neuralgia	neuralgia	neuralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
motor	NN	motor	motor	motor	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
hypotonia	NN	hypotonia	hypotonia	hypotonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
polyneuropathy	NN	polyneuropathy	polyneuropathy	polyneuropathi	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
vision	NN	vision	vision	vision	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
;	:	;	;	;	N	O
comprised	VBN	comprised	comprised	compris	N	O
of	IN	of	of	of	N	O
vision	NN	vision	vision	vision	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
,	,	,	,	,	N	O
blurred	VBN	blurred	blurred	blur	N	B-AdverseReaction
vision	NN	vision	vision	vision	N	I-AdverseReaction
,	,	,	,	,	N	O
photopsia	NN	photopsia	photopsia	photopsia	Y	B-AdverseReaction
,	,	,	,	,	N	O
accommodation	NN	accommodation	accommodation	accommod	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
presbyopia	NN	presbyopia	presbyopia	presbyopia	Y	B-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
reduced	VBN	reduced	reduced	reduc	N	B-AdverseReaction
visual	JJ	visual	visual	visual	N	I-AdverseReaction
acuity	NN	acuity	acuity	acuiti	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
prolonged	VBD	prolonged	prolonged	prolong	N	B-AdverseReaction
QT	NNP	qt	qt	qt	N	I-AdverseReaction
interval	NN	interval	interval	interv	N	I-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Key	NNP	key	key	key	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
Occurring	NNP	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
(	(	(	(	(	N	O
All	DT	all	all	all	N	O
NCI	NNP	nci	nci	nci	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
Grades	NNP	grades	grade	grade	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
ALK	NNP	alk	alk	alk	N	O
-	:	-	-	-	N	O
Positive	JJ	positive	positive	posit	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

ZYKADIAN	$	zykadian	zykadian	zykadian	N	O
255	CD	255	255	255	N	O

All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O

Hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction

decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
84	CD	84	84	84	N	O
5	CD	5	5	5	N	O

Alanine	NNP	alanine	alanine	alanin	N	B-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
)	)	)	)	)	N	O
increased	VBD	increased	increased	increas	N	I-AdverseReaction
80	CD	80	80	80	N	O
27	CD	27	27	27	N	O

Aspartate	NNP	aspartate	aspartate	aspart	N	B-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
(	(	(	(	(	N	O
AST	NNP	ast	ast	ast	N	B-AdverseReaction
)	)	)	)	)	N	O
increased	VBD	increased	increased	increas	N	I-AdverseReaction
75	CD	75	75	75	N	O
13	CD	13	13	13	N	O

Creatinine	NNP	creatinine	creatinine	creatinin	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
58	CD	58	58	58	N	O
2	CD	2	2	2	N	O

Glucose	NNP	glucose	glucose	glucos	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
49	CD	49	49	49	N	O
13	CD	13	13	13	N	O

Phosphate	NNP	phosphate	phosphate	phosphat	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
36	CD	36	36	36	N	O
7	CD	7	7	7	N	O

Lipase	NNP	lipase	lipase	lipas	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
28	CD	28	28	28	N	O
10	CD	10	10	10	N	O

Bilirubin	NNP	bilirubin	bilirubin	bilirubin	Y	B-AdverseReaction
(	(	(	(	(	N	O
total	JJ	total	total	total	N	I-AdverseReaction
)	)	)	)	)	N	O
increased	VBD	increased	increased	increas	N	I-AdverseReaction
15	CD	15	15	15	N	O
1	CD	1	1	1	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Severe	JJ	severe	severe	sever	N	O
or	CC	or	or	or	N	O
Persistent	JJ	persistent	persistent	persist	N	O
Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O
:	:	:	:	:	N	O
Dose	JJ	dose	dose	dose	N	O
modification	NN	modification	modification	modif	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
diarrhea	VB	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
or	CC	or	or	or	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
38%	CD	38%	38%	38%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Withhold	VB	withhold	withhold	withhold	N	O
if	IN	if	if	if	N	O
not	RB	not	not	not	N	O
responsive	JJ	responsive	responsive	respons	N	O
to	TO	to	to	to	N	O
anti	VB	anti	anti	anti	N	O
-	:	-	-	-	N	O
emetics	NNS	emetics	emetic	emet	N	O
or	CC	or	or	or	N	O
anti	VB	anti	anti	anti	N	O
-	:	-	-	-	N	O
diarrheals	NNS	diarrheals	diarrheals	diarrheal	N	O
,	,	,	,	,	N	O
then	RB	then	then	then	N	O
dose	VB	dose	dose	dose	N	O
reduce	VB	reduce	reduce	reduc	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
,	,	,	,	,	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
:	:	:	:	:	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
liver	JJ	liver	liver	liver	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
tests	NNS	tests	test	test	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
monthly	JJ	monthly	monthly	monthli	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
then	RB	then	then	then	N	O
dose	VBD	dose	dose	dose	N	O
reduce	VB	reduce	reduce	reduc	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
Lung	NNP	lung	lung	lung	N	I-AdverseReaction
Disease	NNP	disease	disease	diseas	N	I-AdverseReaction
(	(	(	(	(	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
)	)	)	)	)	N	O
Pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
:	:	:	:	:	N	O
Occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
diagnosed	VBN	diagnosed	diagnosed	diagnos	N	O
with	IN	with	with	with	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
ILD	NNP	ild	ild	ild	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
,	,	,	,	,	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

QT	NNP	qt	qt	qt	N	B-AdverseReaction
Interval	NNP	interval	interval	interv	N	I-AdverseReaction
Prolongation	NNP	prolongation	prolongation	prolong	N	I-AdverseReaction
:	:	:	:	:	N	O
ZYKADIA	NN	zykadia	zykadia	zykadia	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
QTc	NNP	qtc	qtc	qtc	Y	B-AdverseReaction
interval	JJ	interval	interval	interv	N	I-AdverseReaction
prolongation	NN	prolongation	prolongation	prolong	N	I-AdverseReaction
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
electrocardiograms	NNS	electrocardiograms	electrocardiogram	electrocardiogram	N	O
and	CC	and	and	and	N	O
electrolytes	NNS	electrolytes	electrolyte	electrolyt	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
congestive	JJ	congestive	congestive	congest	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
,	,	,	,	,	N	O
bradyarrhythmias	NN	bradyarrhythmias	bradyarrhythmias	bradyarrhythmia	N	O
,	,	,	,	,	N	O
electrolyte	JJ	electrolyte	electrolyte	electrolyt	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
those	DT	those	those	those	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
taking	VBG	taking	taking	take	N	O
medications	NNS	medications	medication	medic	N	O
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
prolong	VB	prolong	prolong	prolong	N	O
the	DT	the	the	the	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
interval	NN	interval	interval	interv	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
then	RB	then	then	then	N	O
dose	VBD	dose	dose	dose	N	O
reduce	VB	reduce	reduce	reduc	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
,	,	,	,	,	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
:	:	:	:	:	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
fasting	VBG	fasting	fasting	fast	Y	O
glucose	RB	glucose	glucose	glucos	Y	O
prior	JJ	prior	prior	prior	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

Initiate	NNP	initiate	initiate	initi	N	O
or	CC	or	or	or	N	O
optimize	VB	optimize	optimize	optim	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
hyperglycemic	JJ	hyperglycemic	hyperglycemic	hyperglycem	N	O
medications	NNS	medications	medication	medic	N	O
as	IN	as	a	as	N	O
indicated	JJ	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
then	RB	then	then	then	N	O
dose	VBD	dose	dose	dose	N	O
reduce	VB	reduce	reduce	reduc	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
,	,	,	,	,	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Bradycardia	NNP	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
:	:	:	:	:	N	O
ZYKADIA	NN	zykadia	zykadia	zykadia	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
heart	NN	heart	heart	heart	N	O
rate	NN	rate	rate	rate	N	O
and	CC	and	and	and	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
regularly	RB	regularly	regularly	regularli	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
then	RB	then	then	then	N	O
dose	VBD	dose	dose	dose	N	O
reduce	VB	reduce	reduce	reduc	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
,	,	,	,	,	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
:	:	:	:	:	N	O
Elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
lipase	NN	lipase	lipase	lipas	Y	I-AdverseReaction
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
amylase	NN	amylase	amylase	amylas	Y	I-AdverseReaction
and	CC	and	and	and	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
lipase	NN	lipase	lipase	lipas	Y	O
and	CC	and	and	and	N	O
amylase	NN	amylase	amylase	amylas	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
,	,	,	,	,	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

Embryofetal	JJ	embryofetal	embryofetal	embryofet	N	B-AdverseReaction
Toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
may	MD	may	may	may	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
.	.	.	.	.	N	O

Advise	NNP	advise	advise	advis	N	O
females	NNS	females	female	femal	N	O
of	IN	of	of	of	N	O
reproductive	JJ	reproductive	reproductive	reproduct	N	O
potential	NN	potential	potential	potenti	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
fetus	NN	fetus	fetus	fetu	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
,	,	,	,	,	N	O
8.1	CD	8.1	8.1	8.1	N	O
,	,	,	,	,	N	O
8.7	CD	8.7	8.7	8.7	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Severe	JJ	severe	severe	sever	N	O

or	CC	or	or	or	N	O
Persistent	NNP	persistent	persistent	persist	N	O
Gastrointestinal	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	O
Toxicity	NNP	toxicity	toxicity	toxic	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
96%	CD	96%	96%	96%	N	O
of	IN	of	of	of	N	O
255	CD	255	255	255	N	O
patients	NNS	patients	patient	patient	N	O
including	VBG	including	including	includ	N	O
severe	JJ	severe	severe	sever	N	B-Severity
cases	NNS	cases	case	case	N	O
in	IN	in	in	in	N	O
14%	CD	14%	14%	14%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Dose	NNP	dose	dose	dose	N	O
modification	NN	modification	modification	modif	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
diarrhea	VB	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
38%	CD	38%	38%	38%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
and	CC	and	and	and	N	O
manage	NN	manage	manage	manag	N	O
patients	NNS	patients	patient	patient	N	O
using	VBG	using	using	use	N	O
standards	NNS	standards	standard	standard	N	O
of	IN	of	of	of	N	O
care	NN	care	care	care	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
diarrheals	NNS	diarrheals	diarrheals	diarrheal	N	O
,	,	,	,	,	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
emetics	NNS	emetics	emetic	emet	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
fluid	JJ	fluid	fluid	fluid	N	O
replacement	NN	replacement	replacement	replac	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reaction	NN	reaction	reaction	reaction	N	O
,	,	,	,	,	N	O
withhold	JJ	withhold	withhold	withhold	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
with	IN	with	with	with	N	O
resumption	NN	resumption	resumption	resumpt	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
reduced	JJ	reduced	reduced	reduc	N	O
dose	NN	dose	dose	dose	N	O
as	IN	as	a	as	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
[	NN	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	O

Drug	NNP	drug	drug	drug	N	O
-	:	-	-	-	N	O
induced	JJ	induced	induced	induc	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
.	.	.	.	.	N	O

Elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
alanine	JJ	alanine	alanine	alanin	N	I-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	O
)	)	)	)	)	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
5	CD	5	5	5	N	B-Severity
times	NNS	times	time	time	N	I-Severity
the	DT	the	the	the	N	I-Severity
upper	JJ	upper	upper	upper	N	I-Severity
limit	NN	limit	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
(	(	(	(	(	N	O
ULN	NNP	uln	uln	uln	N	O
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
27%	CD	27%	27%	27%	N	O
of	IN	of	of	of	N	O
255	CD	255	255	255	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

One	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
(	(	(	(	(	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
)	)	)	)	)	N	O
required	VBN	required	required	requir	N	O
permanent	JJ	permanent	permanent	perman	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
elevated	JJ	elevated	elevated	elev	N	B-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
jaundice	NN	jaundice	jaundice	jaundic	Y	B-AdverseReaction
.	.	.	.	.	N	O

Concurrent	JJ	concurrent	concurrent	concurr	N	O
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
3	CD	3	3	3	N	B-Severity
times	NNS	times	time	time	N	I-Severity
the	DT	the	the	the	N	I-Severity
ULN	NNP	uln	uln	uln	N	I-Severity
and	CC	and	and	and	N	O
total	JJ	total	total	total	N	B-AdverseReaction
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
2	CD	2	2	2	N	I-AdverseReaction
times	NNS	times	time	time	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
ULN	NNP	uln	uln	uln	N	I-AdverseReaction
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
normal	JJ	normal	normal	normal	N	O
alkaline	JJ	alkaline	alkaline	alkalin	N	O
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	O
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
with	IN	with	with	with	N	O
liver	JJ	liver	liver	liver	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
tests	NNS	tests	test	test	N	O
including	VBG	including	including	includ	N	O
ALT	NNP	alt	alt	alt	N	O
,	,	,	,	,	N	O
aspartate	JJ	aspartate	aspartate	aspart	N	O
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	O
(	(	(	(	(	N	O
AST	NNP	ast	ast	ast	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
total	JJ	total	total	total	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O
once	RB	once	once	onc	N	O
a	DT	a	a	a	N	O
month	NN	month	month	month	N	O
and	CC	and	and	and	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
indicated	VBN	indicated	indicated	indic	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
testing	NN	testing	testing	test	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
transaminase	JJ	transaminase	transaminase	transaminas	N	O
elevations	NNS	elevations	elevation	elev	N	O
.	.	.	.	.	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reaction	NN	reaction	reaction	reaction	N	O
,	,	,	,	,	N	O
withhold	JJ	withhold	withhold	withhold	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
with	IN	with	with	with	N	O
resumption	NN	resumption	resumption	resumpt	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
reduced	JJ	reduced	reduced	reduc	N	O
dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
as	IN	as	a	as	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
[	NN	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Interstitial	JJ	interstitial	interstitial	interstiti	N	O
Lung	NNP	lung	lung	lung	N	O
Disease	NNP	disease	disease	diseas	N	O
(	(	(	(	(	N	O
ILD	NNP	ild	ild	ild	N	O
)	)	)	)	)	N	O
Pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O

Severe	NNP	severe	severe	sever	N	B-Severity
,	,	,	,	,	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
255	CD	255	255	255	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
.	.	.	.	.	N	O

CTCAE	NNP	ctcae	ctcae	ctcae	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
4	CD	4	4	4	N	I-Severity
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
patient	NN	patient	patient	patient	N	O
(	(	(	(	(	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

One	CD	one	one	one	N	O
percent	NN	percent	percent	percent	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
ILD	NNP	ild	ild	ild	N	B-AdverseReaction
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
indicative	JJ	indicative	indicative	indic	N	O
of	IN	of	of	of	N	O
ILD	NNP	ild	ild	ild	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O
.	.	.	.	.	N	O

Exclude	NNP	exclude	exclude	exclud	N	O
other	JJ	other	other	other	N	O
potential	JJ	potential	potential	potenti	N	O
causes	NNS	causes	cause	caus	N	O
of	IN	of	of	of	N	O
ILD	NNP	ild	ild	ild	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
diagnosed	VBN	diagnosed	diagnosed	diagnos	N	O
with	IN	with	with	with	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
ILD	NNP	ild	ild	ild	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
QT	NNP	qt	qt	qt	N	O
Interval	NNP	interval	interval	interv	N	O
Prolongation	NNP	prolongation	prolongation	prolong	N	O

QTc	NNP	qtc	qtc	qtc	Y	B-AdverseReaction
interval	JJ	interval	interval	interv	N	I-AdverseReaction
prolongation	NN	prolongation	prolongation	prolong	N	I-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
ventricular	JJ	ventricular	ventricular	ventricular	N	B-AdverseReaction
tachyarrhythmias	NN	tachyarrhythmias	tachyarrhythmias	tachyarrhythmia	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
Torsade	NNP	torsade	torsade	torsad	N	B-AdverseReaction
de	FW	de	de	de	N	I-AdverseReaction
pointes	NNS	pointes	pointes	point	N	I-AdverseReaction
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
sudden	JJ	sudden	sudden	sudden	N	B-AdverseReaction
death	NN	death	death	death	Y	I-AdverseReaction
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Three	CD	three	three	three	N	O
percent	NN	percent	percent	percent	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
255	CD	255	255	255	N	O
patients	NNS	patients	patient	patient	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
QTc	NNP	qtc	qtc	qtc	Y	B-AdverseReaction
interval	JJ	interval	interval	interv	N	I-AdverseReaction
increase	NN	increase	increase	increas	N	I-AdverseReaction
over	IN	over	over	over	N	O
baseline	NN	baseline	baseline	baselin	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
60	CD	60	60	60	N	B-Severity
msec	NN	msec	msec	msec	N	I-Severity
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Across	IN	across	across	across	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
program	NN	program	program	program	N	O
of	IN	of	of	of	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
of	IN	of	of	of	N	O
304	CD	304	304	304	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
doses	NNS	doses	dos	dose	N	O
ranging	VBG	ranging	ranging	rang	N	O
from	IN	from	from	from	N	O
50	CD	50	50	50	N	O
to	TO	to	to	to	N	O
750	CD	750	750	750	N	O
mg	NN	mg	mg	mg	N	O
was	VBD	was	wa	wa	N	O
found	VBN	found	found	found	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
a	DT	a	a	a	N	O
QTc	NNP	qtc	qtc	qtc	Y	B-AdverseReaction
greater	JJR	greater	greater	greater	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
500	CD	500	500	500	N	I-AdverseReaction
msec	NNS	msec	msec	msec	N	I-AdverseReaction
and	CC	and	and	and	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
from	IN	from	from	from	N	I-AdverseReaction
baseline	JJ	baseline	baseline	baselin	N	I-AdverseReaction
QTc	NNP	qtc	qtc	qtc	Y	I-AdverseReaction
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
60	CD	60	60	60	N	B-Severity
msec	NN	msec	msec	msec	N	I-Severity
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
pharmacokinetic	JJ	pharmacokinetic	pharmacokinetic	pharmacokinet	N	O
analysis	NN	analysis	analysis	analysi	N	O
suggested	VBD	suggested	suggested	suggest	N	B-Factor
that	IN	that	that	that	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
causes	VBZ	causes	cause	caus	N	O
concentration	NN	concentration	concentration	concentr	N	O
-	:	-	-	-	N	O
dependent	NN	dependent	dependent	depend	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
QTc	NNP	qtc	qtc	qtc	Y	I-AdverseReaction
interval	NN	interval	interval	interv	N	I-AdverseReaction
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
possible	JJ	possible	possible	possibl	N	O
,	,	,	,	,	N	O
avoid	JJ	avoid	avoid	avoid	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
congenital	JJ	congenital	congenital	congenit	N	O
long	JJ	long	long	long	N	O
QT	NNP	qt	qt	qt	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
.	.	.	.	.	N	O

Conduct	NNP	conduct	conduct	conduct	N	O
periodic	JJ	periodic	periodic	period	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
with	IN	with	with	with	N	O
electrocardiograms	NNS	electrocardiograms	electrocardiogram	electrocardiogram	N	O
(	(	(	(	(	N	O
ECGs	NNP	ecgs	ecg	ecg	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
electrolytes	VBZ	electrolytes	electrolyte	electrolyt	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
congestive	JJ	congestive	congestive	congest	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
,	,	,	,	,	N	O
bradyarrhythmias	NN	bradyarrhythmias	bradyarrhythmias	bradyarrhythmia	N	O
,	,	,	,	,	N	O
electrolyte	JJ	electrolyte	electrolyte	electrolyt	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
those	DT	those	those	those	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
taking	VBG	taking	taking	take	N	O
medications	NNS	medications	medication	medic	N	O
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
prolong	VB	prolong	prolong	prolong	N	O
the	DT	the	the	the	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
interval	NN	interval	interval	interv	N	O
.	.	.	.	.	N	O

Withhold	JJ	withhold	withhold	withhold	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
a	DT	a	a	a	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
interval	NN	interval	interval	interv	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
500	CD	500	500	500	N	O
msec	NN	msec	msec	msec	N	O
on	IN	on	on	on	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2	CD	2	2	2	N	O
separate	JJ	separate	separate	separ	N	O
ECGs	NNP	ecgs	ecg	ecg	N	O
until	IN	until	until	until	N	O
the	DT	the	the	the	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
interval	NN	interval	interval	interv	N	O
is	VBZ	is	is	is	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
481	CD	481	481	481	N	O
msec	NN	msec	msec	msec	N	O
or	CC	or	or	or	N	O
recovery	NN	recovery	recovery	recoveri	N	O
to	TO	to	to	to	N	O
baseline	VB	baseline	baseline	baselin	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
interval	NN	interval	interval	interv	N	O
is	VBZ	is	is	is	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
481	CD	481	481	481	N	O
msec	NNS	msec	msec	msec	N	O
,	,	,	,	,	N	O
then	RB	then	then	then	N	O
resume	VB	resume	resume	resum	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
reduced	JJ	reduced	reduced	reduc	N	O
dose	NN	dose	dose	dose	N	O
as	IN	as	a	as	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
interval	JJ	interval	interval	interv	N	O
prolongation	NN	prolongation	prolongation	prolong	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
Torsade	NNP	torsade	torsade	torsad	N	O
de	FW	de	de	de	N	O
pointes	VBZ	pointes	pointes	point	N	O
or	CC	or	or	or	N	O
polymorphic	JJ	polymorphic	polymorphic	polymorph	N	O
ventricular	JJ	ventricular	ventricular	ventricular	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	O
or	CC	or	or	or	N	O
signs	NNS	signs	sign	sign	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	O
arrhythmia	NN	arrhythmia	arrhythmia	arrhythmia	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.2	CD	12.2	12.2	12.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	O

Hyperglycemia	NNP	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
values	NNS	values	value	valu	N	O
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
13%	CD	13%	13%	13%	N	O
of	IN	of	of	of	N	O
255	CD	255	255	255	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
a	DT	a	a	a	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
fold	JJ	fold	fold	fold	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
or	CC	or	or	or	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
intolerance	NN	intolerance	intolerance	intoler	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
fold	JJ	fold	fold	fold	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
fasting	VBG	fasting	fasting	fast	Y	O
serum	NN	serum	serum	serum	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
start	NN	start	start	start	N	O
of	IN	of	of	of	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

Initiate	NNP	initiate	initiate	initi	N	O
or	CC	or	or	or	N	O
optimize	VB	optimize	optimize	optim	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
hyperglycemic	JJ	hyperglycemic	hyperglycemic	hyperglycem	N	O
medications	NNS	medications	medication	medic	N	O
as	IN	as	a	as	N	O
indicated	JJ	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reaction	NN	reaction	reaction	reaction	N	O
,	,	,	,	,	N	O
withhold	JJ	withhold	withhold	withhold	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
until	IN	until	until	until	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	O
is	VBZ	is	is	is	N	O
adequately	RB	adequately	adequately	adequ	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
then	RB	then	then	then	N	O
resume	VB	resume	resume	resum	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
reduced	JJ	reduced	reduced	reduc	N	O
dose	NN	dose	dose	dose	N	O
as	IN	as	a	as	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
adequate	JJ	adequate	adequate	adequ	N	O
hyperglycemic	NNS	hyperglycemic	hyperglycemic	hyperglycem	N	O
control	NN	control	control	control	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
achieved	VBN	achieved	achieved	achiev	N	O
with	IN	with	with	with	N	O
optimal	JJ	optimal	optimal	optim	N	O
medical	JJ	medical	medical	medic	N	O
management	NN	management	management	manag	N	O
,	,	,	,	,	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinue	VBP	discontinue	discontinue	discontinu	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Bradycardia	NNP	bradycardia	bradycardia	bradycardia	Y	O

Bradycardia	NNP	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
sinus	NN	sinus	sinus	sinu	N	B-AdverseReaction
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	I-AdverseReaction
,	,	,	,	,	N	O
defined	VBD	defined	defined	defin	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
heart	NN	heart	heart	heart	N	B-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
less	JJR	less	le	less	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
50	CD	50	50	50	N	I-AdverseReaction
beats	NNS	beats	beat	beat	N	I-AdverseReaction
per	IN	per	per	per	N	I-AdverseReaction
minute	NN	minute	minute	minut	N	I-AdverseReaction
,	,	,	,	,	N	O
was	VBD	was	wa	wa	N	O
noted	VBN	noted	noted	note	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
new	JJ	new	new	new	N	O
finding	NN	finding	finding	find	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
255	CD	255	255	255	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Bradycardia	NNP	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reaction	NN	reaction	reaction	reaction	N	O
in	IN	in	in	in	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Avoid	NNP	avoid	avoid	avoid	N	O
using	VBG	using	using	use	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
agents	NNS	agents	agent	agent	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
cause	VB	cause	cause	caus	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
beta	SYM	beta	beta	beta	N	O
-	:	-	-	-	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
dihydropyridine	NN	dihydropyridine	dihydropyridine	dihydropyridin	N	O
calcium	NN	calcium	calcium	calcium	Y	O
channel	NN	channel	channel	channel	N	O
blockers	NNS	blockers	blocker	blocker	N	O
,	,	,	,	,	N	O
clonidine	NN	clonidine	clonidine	clonidin	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
digoxin	NN	digoxin	digoxin	digoxin	N	O
)	)	)	)	)	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
extent	NN	extent	extent	extent	N	O
possible	JJ	possible	possible	possibl	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
heart	NN	heart	heart	heart	N	O
rate	NN	rate	rate	rate	N	O
and	CC	and	and	and	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
regularly	RB	regularly	regularly	regularli	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	O
that	WDT	that	that	that	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	NN	threatening	threatening	threaten	N	O
,	,	,	,	,	N	O
withhold	JJ	withhold	withhold	withhold	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
until	IN	until	until	until	N	O
recovery	NN	recovery	recovery	recoveri	N	O
to	TO	to	to	to	N	O
asymptomatic	JJ	asymptomatic	asymptomatic	asymptomat	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	O
or	CC	or	or	or	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
heart	NN	heart	heart	heart	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
60	CD	60	60	60	N	O
bpm	NN	bpm	bpm	bpm	N	O
or	CC	or	or	or	N	O
above	IN	above	above	abov	N	O
,	,	,	,	,	N	O
evaluate	VB	evaluate	evaluate	evalu	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
adjust	VBP	adjust	adjust	adjust	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
for	IN	for	for	for	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	JJ	threatening	threatening	threaten	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	O
if	IN	if	if	if	N	O
no	DT	no	no	no	N	O
contributing	VBG	contributing	contributing	contribut	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medication	NN	medication	medication	medic	N	O
is	VBZ	is	is	is	N	O
identified	VBN	identified	identified	identifi	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
if	IN	if	if	if	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medication	NN	medication	medication	medic	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
cause	VB	cause	cause	caus	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	O
or	CC	or	or	or	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
,	,	,	,	,	N	O
withhold	JJ	withhold	withhold	withhold	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
until	IN	until	until	until	N	O
recovery	NN	recovery	recovery	recoveri	N	O
to	TO	to	to	to	N	O
asymptomatic	JJ	asymptomatic	asymptomatic	asymptomat	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	O
or	CC	or	or	or	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
heart	NN	heart	heart	heart	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
60	CD	60	60	60	N	O
bpm	NN	bpm	bpm	bpm	N	O
or	CC	or	or	or	N	O
above	NN	above	above	abov	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medication	NN	medication	medication	medic	N	O
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
adjusted	VBN	adjusted	adjusted	adjust	N	O
or	CC	or	or	or	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
,	,	,	,	,	N	O
resume	VB	resume	resume	resum	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
reduced	JJ	reduced	reduced	reduc	N	O
dose	NN	dose	dose	dose	N	O
as	IN	as	a	as	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
upon	JJ	upon	upon	upon	N	O
recovery	NN	recovery	recovery	recoveri	N	O
to	TO	to	to	to	N	O
asymptomatic	JJ	asymptomatic	asymptomatic	asymptomat	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	O
or	CC	or	or	or	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
heart	NN	heart	heart	heart	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
60	CD	60	60	60	N	O
bpm	NN	bpm	bpm	bpm	N	O
or	CC	or	or	or	N	O
above	IN	above	above	abov	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
frequent	JJ	frequent	frequent	frequent	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O

Pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
one	CD	one	one	one	N	O
fatality	NN	fatality	fatality	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

CTCAE	NNP	ctcae	ctcae	ctcae	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
lipase	NN	lipase	lipase	lipas	Y	I-AdverseReaction
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
amylase	VB	amylase	amylase	amylas	Y	I-AdverseReaction
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
15%	CD	15%	15%	15%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
lipase	NN	lipase	lipase	lipas	Y	O
and	CC	and	and	and	N	O
amylase	NN	amylase	amylase	amylas	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
start	NN	start	start	start	N	O
of	IN	of	of	of	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
indicated	VBN	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
severity	NN	severity	severity	sever	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
,	,	,	,	,	N	O
withhold	JJ	withhold	withhold	withhold	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
with	IN	with	with	with	N	O
resumption	NN	resumption	resumption	resumpt	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
reduced	JJ	reduced	reduced	reduc	N	O
dose	NN	dose	dose	dose	N	O
as	IN	as	a	as	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
[	NN	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Embryofetal	JJ	embryofetal	embryofetal	embryofet	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
its	PRP$	its	it	it	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
of	IN	of	of	of	N	O
action	NN	action	action	action	N	O
,	,	,	,	,	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
may	MD	may	may	may	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
animal	JJ	animal	animal	anim	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
ceritinib	NN	ceritinib	ceritinib	ceritinib	N	O
to	TO	to	to	to	N	O
rats	NNS	rats	rat	rat	N	O
and	CC	and	and	and	N	O
rabbits	NNS	rabbits	rabbit	rabbit	N	O
during	IN	during	during	dure	N	O
organogenesis	NN	organogenesis	organogenesis	organogenesi	N	O
at	IN	at	at	at	N	O
maternal	JJ	maternal	maternal	matern	N	O
plasma	NN	plasma	plasma	plasma	N	O
exposures	NNS	exposures	exposure	exposur	N	O
below	IN	below	below	below	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
human	JJ	human	human	human	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
750	CD	750	750	750	N	O
mg	JJ	mg	mg	mg	N	O
daily	RB	daily	daily	daili	N	O
caused	VBN	caused	caused	caus	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
skeletal	JJ	skeletal	skeletal	skelet	N	I-AdverseReaction
anomalies	NNS	anomalies	anomaly	anomali	N	I-AdverseReaction
in	IN	in	in	in	N	O
rats	NNS	rats	rat	rat	N	B-Animal
and	CC	and	and	and	N	O
rabbits	NNS	rabbits	rabbit	rabbit	N	B-Animal
.	.	.	.	.	N	O

Apprise	NNP	apprise	apprise	appris	N	O
women	NNS	women	woman	women	N	O
of	IN	of	of	of	N	O
reproductive	JJ	reproductive	reproductive	reproduct	N	O
potential	NN	potential	potential	potenti	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
hazard	NN	hazard	hazard	hazard	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
fetus	NN	fetus	fetus	fetu	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Advise	NNP	advise	advise	advis	N	O
females	NNS	females	female	femal	N	O
of	IN	of	of	of	N	O
reproductive	JJ	reproductive	reproductive	reproduct	N	O
potential	NN	potential	potential	potenti	N	O
to	TO	to	to	to	N	O
use	VB	use	use	use	N	O
effective	JJ	effective	effective	effect	N	O
contraception	NN	contraception	contraception	contracept	Y	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
ZYKADIA	NNP	zykadia	zykadia	zykadia	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2	CD	2	2	2	N	O
weeks	NNS	weeks	week	week	N	O
following	VBG	following	following	follow	N	O
completion	NN	completion	completion	complet	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.7	CD	8.7	8.7	8.7	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

